Company registration number 09981769 (England and Wales)
FAST BIOPHARMA LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
PAGES FOR FILING WITH REGISTRAR
FAST BIOPHARMA LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
FAST BIOPHARMA LTD
BALANCE SHEET
AS AT
31 JANUARY 2026
31 January 2026
- 1 -
2026
2025
Notes
£
£
£
£
Current assets
Debtors
4
151
150
Cash at bank and in hand
6,642
9,689
6,793
9,839
Creditors: amounts falling due within one year
5
(2,450)
(2,400)
Net current assets
4,343
7,439
Capital and reserves
Called up share capital
6
191
191
Share premium account
373,909
373,909
Profit and loss reserves
(369,757)
(366,661)
Total equity
4,343
7,439

For the financial year ended 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 13 August 2026 and are signed on its behalf by:
P D Davis
Director
Company registration number 09981769 (England and Wales)
FAST BIOPHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
- 2 -
1
Accounting policies
Company information

Fast Biopharma Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 10 Aston Park, Aston Rowant, Watlington, Oxfordshire, OX49 5SW.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
20% straight line
Computers
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

FAST BIOPHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
1
Accounting policies
(Continued)
- 3 -
Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
4
4
Total
4
4
FAST BIOPHARMA LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
- 4 -
3
Tangible fixed assets
Plant and equipment
Computers
Total
£
£
£
Cost
At 1 February 2025 and 31 January 2026
3,458
416
3,874
Depreciation and impairment
At 1 February 2025 and 31 January 2026
3,458
416
3,874
Carrying amount
At 31 January 2026
-
0
-
0
-
0
At 31 January 2025
-
0
-
0
-
0
4
Debtors
2026
2025
Amounts falling due within one year:
£
£
Prepayments and accrued income
151
150
5
Creditors: amounts falling due within one year
2026
2025
£
£
Accruals and deferred income
2,450
2,400
6
Called up share capital
2026
2025
£
£
Ordinary share capital
Issued and fully paid
100,000 Ordinary of 0.001p each
100
100
90,657 A Ordinary of 0.001p each
91
91
191
191
2026-01-31 2025-02-01 false false false 13 August 2026 CCH Software CCH Accounts Production 2026.200 No description of principal activity D J Chaplin P D Davis D Blakey 09981769 2025-02-01 2026-01-31 09981769 2026-01-31 09981769 core:WithinOneYear 2026-01-31 09981769 core:WithinOneYear 2025-01-31 09981769 2025-01-31 09981769 core:CurrentFinancialInstruments core:WithinOneYear 2026-01-31 09981769 core:CurrentFinancialInstruments core:WithinOneYear 2025-01-31 09981769 core:ShareCapital 2026-01-31 09981769 core:ShareCapital 2025-01-31 09981769 core:SharePremium 2026-01-31 09981769 core:SharePremium 2025-01-31 09981769 core:RetainedEarningsAccumulatedLosses 2026-01-31 09981769 core:RetainedEarningsAccumulatedLosses 2025-01-31 09981769 core:ShareCapitalOrdinaryShareClass1 2026-01-31 09981769 core:ShareCapitalOrdinaryShareClass1 2025-01-31 09981769 core:ShareCapitalOrdinaryShareClass2 2026-01-31 09981769 core:ShareCapitalOrdinaryShareClass2 2025-01-31 09981769 core:ShareCapitalOrdinaryShares 2026-01-31 09981769 core:ShareCapitalOrdinaryShares 2025-01-31 09981769 bus:Director2 2025-02-01 2026-01-31 09981769 core:PlantMachinery 2025-02-01 2026-01-31 09981769 core:ComputerEquipment 2025-02-01 2026-01-31 09981769 2024-02-01 2025-01-31 09981769 core:PlantMachinery 2025-01-31 09981769 core:ComputerEquipment 2025-01-31 09981769 2025-01-31 09981769 core:PlantMachinery 2026-01-31 09981769 core:ComputerEquipment 2026-01-31 09981769 core:PlantMachinery 2025-01-31 09981769 core:ComputerEquipment 2025-01-31 09981769 core:CurrentFinancialInstruments 2026-01-31 09981769 core:CurrentFinancialInstruments 2025-01-31 09981769 bus:PrivateLimitedCompanyLtd 2025-02-01 2026-01-31 09981769 bus:SmallCompaniesRegimeForAccounts 2025-02-01 2026-01-31 09981769 bus:FRS102 2025-02-01 2026-01-31 09981769 bus:AuditExemptWithAccountantsReport 2025-02-01 2026-01-31 09981769 bus:Director1 2025-02-01 2026-01-31 09981769 bus:CompanySecretary1 2025-02-01 2026-01-31 09981769 bus:FullAccounts 2025-02-01 2026-01-31 xbrli:pure xbrli:shares iso4217:GBP